UNCY FY2026 EPS Raised by Brookline Capital Management

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) – Investment analysts at Brookline Capital Management increased their FY2026 earnings estimates for shares of Unicycive Therapeutics in a research report issued on Wednesday, November 13th. Brookline Capital Management analyst K. Raja now anticipates that the company will post earnings of $1.88 per share for the year, up from their prior forecast of $1.85. The consensus estimate for Unicycive Therapeutics’ current full-year earnings is ($0.26) per share. Brookline Capital Management also issued estimates for Unicycive Therapeutics’ FY2027 earnings at $2.58 EPS and FY2028 earnings at $1.37 EPS.

A number of other research firms also recently weighed in on UNCY. Benchmark reissued a “speculative buy” rating and set a $3.00 price target on shares of Unicycive Therapeutics in a research report on Friday, September 6th. HC Wainwright reissued a “buy” rating and set a $2.50 price objective on shares of Unicycive Therapeutics in a report on Tuesday. Four investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Unicycive Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $5.13.

Unicycive Therapeutics Stock Up 2.7 %

Shares of NASDAQ UNCY opened at $0.46 on Friday. The business has a 50 day moving average price of $0.43 and a two-hundred day moving average price of $0.55. Unicycive Therapeutics has a fifty-two week low of $0.20 and a fifty-two week high of $1.82. The firm has a market cap of $43.40 million, a PE ratio of -0.47 and a beta of 2.29.

Unicycive Therapeutics (NASDAQ:UNCY) last released its quarterly earnings results on Wednesday, August 14th. The company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.08.

Institutional Investors Weigh In On Unicycive Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the company. XTX Topco Ltd bought a new stake in Unicycive Therapeutics during the third quarter valued at $29,000. Walleye Capital LLC acquired a new position in shares of Unicycive Therapeutics in the 3rd quarter valued at about $2,040,000. Acuta Capital Partners LLC bought a new stake in shares of Unicycive Therapeutics during the 3rd quarter valued at about $807,000. Great Point Partners LLC acquired a new stake in Unicycive Therapeutics during the third quarter worth about $3,491,000. Finally, Bleakley Financial Group LLC bought a new position in Unicycive Therapeutics in the third quarter worth about $33,000. 40.42% of the stock is owned by institutional investors and hedge funds.

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.